ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO506

Increased Expression of NMN Transporter in the Kidneys in Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic


  • Yasuda, Itaru, Keio University, Tokyo, Japan
  • Hasegawa, Kazuhiro, Keio University, Tokyo, Japan
  • Ono, Takashi, Shionogi & Co., Ltd, Osaka, Japan
  • Wakino, Shu, Keio University, Tokyo, Japan
  • Itoh, Hiroshi, Keio University, Tokyo, Japan

In diabetic nephropathy (DN) and aging kidney, renal tissue concentration of nicotinamide adenine dinucleotide (NAD+) decreased, which is associated with renal dysfunction and albuminuria. The regulatory systems of NAD+ and its precursor, nicotinamide mononucleotide (NMN) are considered to play a crucial role in the maintenance of tissue NAD+ levels and the pathogenesis of DN. Recent study identified novel NMN transporter, Solute Carrier Family 12 Member 8 (Slc12a8). However, the role and location of NMN transporter in the kidneys as well as diabetic kidney remain unclear.


Type 2 diabetic db/db and control db/m mice were given regular chow diet ad libitum and euthanized at 24 weeks of age. We performed immunohistochemistry (IHC) of renal Slc12a8. Further, we measured serum and urinary NAD+ metabolites at 24 weeks of age. We evaluated renal NAD+ loss by calculating urine NAD+ to creatinine ratio (NAD+/Cr). NMN resorption was evaluated by the calculation of the fractional excretion of NMN (FeNMN).


Tissue concentration of NAD+ decreased in db/db mice as compared to that in db/m mice at the age of 8 weeks, although that of NMN was not different. Urine NAD+/Cr ratios were higher in db/db mice than in db/m mice, suggesting an increased renal loss of NAD+ in db/db mice. IHC revealed weak staining of Slc12a8 in the glomerulus and proximal tubules, while strong staining in the distal tubules. Slc12a8 expression was higher in db/db mice than in db/m mice. While the expression of Slc12a8 was detected mostly on the basolateral side in db/m mice, it was expressed on both apical and basolateral side in db/db mice. These findings suggested the increased translocation of Slc12a8 towards apical side of distal tubular cells in DN. Consistently, FeNMN was lower in db/db mice than that in db/m mice, indicating increased resorption NMN at the tubules in db/db mice.


Novel NMN transporter, Slc12a8 was dominantly expressed in the distal tubules. In DN, Slc12a8 translocation to apical side was enhanced, which can be the compensatory mechanism for NAD+ loss in diabetic mice.